anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Currently, there is limited access to movement disorder specialist centers for a significant portion of the PD population. Treatment effectiveness is judged during office visits by improvement of patient motor symptoms and quality of life. Clinicians evaluate patients by having them perform specific motor tasks and rating the severity on a 0-4 scale. A major limitation is that a single evaluation in a clinical setting may not accurately reflect motor symptom fluctuations experienced over the course of a day, week, or month. Clinicians currently lack effective, affordable medical devices that can be easily delivered to a patient's home for monitoring symptoms on a more continuous basis as motor symptoms typically change throughout the day. Kinesia HomeView provides a repeatable, automated system clinicians can use to remotely monitor PD motor symptoms on a more continuous basis in a patient's home. The investigators hypothesize use of the Kinesia HomeView system will improve outcomes and decrease costs especially for patient populations in areas not in close proximity to movement disorder specialists.
The bioassay guided isolation and characterization of a novel antimicrobial peptide called myxinidin from an acidic extract of the epidermal mucus of hagfish ( Myxine glutinosa  L.) is disclosed. Detection of myxinidin in the extract of extruded hagfish slime is also disclosed. Myxinidin exhibited microbicidal activity against a wide range of microbial pathogens and no toxicity to mammalian red blood cells. Human pathogens  Escherichia  
 coli  D31 and  Salmonella enterica  C610 and fish pathogens  Aeromonas salmonicida  A449,  Yersinia ruckeri  96-4 and  Listonella anguillarum  02-11, were found to be the most sensitive to the myxinidin. Edman sequencing and mass spectrometry indicated that myxinidin consists of 12 amino acids and a molecular mass of 1327.68  m/z  [M+ H]+. The microbicidal activity of myxinidin was observed to be retained at sodium salt concentrations for up to 0.3 M. The concentration of myxinidin in the dried crude extruded slime was determined to be 0.37 mg/g. The total protein concentration of the extruded slime indicated that myxinidin contributed 0.13% to the total extruded slime protein. It was observed that the myxinidin in the extruded slime acid extract did not contribute significantly to the overall antimicrobial activity, suggesting that the acidic extract of the extruded slime contains other antimicrobial components. The instant invention suggests myxinidin can be alternate therapeutic agent for fish and human health related applications.
A method of imparting enduring beneficial features to a hard flocked surface of an article is provided. The method includes encapsulating a desired beneficial agent as a core material in a polymeric microcapsule, and transferring polymeric microcapsule to the surface by a dipping, spraying, or padding application. The beneficial agent, after getting transferred to the surface of a hard flocked article, imparts long lasting performance, provides fragrance and may protect an article from odor, insect, pest, fungi, bacteria, viruses, and the like. The polymeric microcapsules deliver long lasting benefits to surfaces with flocking, such as clothes hangers. Also described is a process for manufacture of flocked items with benefit delivering polymer microcapsules, without the need for binders or adhesives. Benefit agents are released with shear force on the flocked surface, so they are released when used and provide long-lasting performance.
Atrial fibrillation is the most frequent cardiac arrhythmia in old age. As a result of the positive data on ablation, the focus has shifted to rhythm control. Older adults can also benefit from catheter ablation. Oral anticoagulation remains an essential part of the pharmacological treatment of atrial fibrillation. Recent study results show that geriatric patients require an individual treatment approach, which should be based on the recommendations of the current guidelines and the use of supplementary aids. The assessment of functionality should be taken into account in the treatment and the treatment goal planning as well as symptoms associated with atrial fibrillation. In acute situations cardioversion and long-term drug or interventional (catheter ablation) rhythm-stabilizing treatment are available for rhythm control.
PURPOSE:To perform the baking to the surface of a crown material relatively low in heat-resistant temp. at low temp., to make the compatibility and adhesion with a base material excellent and to make the long-term use in the oral cavity possible by using a phosphate type glass stain material having a specific composition. CONSTITUTION:As starting raw materials, a phosphorus-containing compound forming phosphorous oxide by baking such as phosphoric acid or polyphosphoric acid and a compound capable of becoming aluminum oxide by baking such as alumina, aluminum hydroxide or aluminum nitrate are used. As alkali metal oxide (R2O), one or more kind of compound selected from a group consisting of Li2O, Na2O, K2O, Rb2O, Cs2O and Fr2O is used. A composition is set so that P2O5 is 30-80wt.%, Al2O3 is 1-20wt.%, R2O is 1-30wt.% and the fourth component such as ZnO is 0.5-50wt.%. For the purpose of enhancing aesthetic properties, one or more kind of a colorant component selected from a group consisting of oxides of Ni, Ce, Ti, V, Cr, Mn, Fe, Co, Zn, W, Ru, Mo, Rh, Hf, Ph, Pr, U, Ag and Au is added..
PURPOSE:To efficiently extract propolis tincture as components by washing raw lump of propolis tincture, forming an extracted solution with an alcohol, forming an ion extracted solution and finally carrying out blending process successively and to process the propolis tincture into a given state by a given processing route. CONSTITUTION:Raw lump of propolis is put in a sealed tank, stirred with an alcohol for food and the supernatant liquid is filtered (washed). The filtrate is mixed with a new alcohol for food, restirred and the supernatant liquid is filtered. Simultaneously new raw lump of propolis is added to the sealed tank, stirred with the filtered and purified extracted solution and filtered to give an alcohol extracted solution. Then ionized water is added to the tank containing the raw lump of propolis from which the alcohol extracted solution is removed and stirred under heating to give an ion extracted solution. Finally the alcohol extracted solution is mixed with the ion extracted solution, settled and the supernatant liquid is filtered to extract propolis tincture. Further propolis tincture is mixed with fats and oils, stirred and subjected to a given processing. By this method, components are extracted efficiently.
Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.
Participants will receive Computerized Cognitive Training and sham tDCS daily for one month. Sham stimulation will consist of 60 seconds of anodal 2mA tDCS stimulation over the DLPFC, followed by 19 mins of no current delivery. The same 15 min of computerized cognitive training will be provided after the end of the Sham Stimulation.
Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using CO2 insufflation.
Devices, systems, and methods are provided for adherence monitoring and patient interaction. In general, the devices, systems, and methods can facilitate a patient's adherence to a medication schedule and can facilitate monitoring and tracking of the patient's adherence to the medication schedule. In one embodiment, a medical accessory such as a cap is provided that can be configured to attach to existing medication dispensers, such as asthma inhalers, or to be integrated into a custom-made medication dispenser. The accessory can be configured to provide a notification to the patient when medication is due. The accessory can be configured to detect usage of the dispenser. The accessory can be configured to provide data regarding dispensing of the medication to an external device. The data can be analyzed and provided for visualization on a user interface.
Heterogeneous nuclear ribonucleoprotein D (HNRNPD) can regulate expression of key proteins in various cancers. However, the prognostic predictive value and biology function of HNRNPD in non-small cell lung cancer (NSCLC) is unknown. First, we used the TCGA and GEO datasets to determine that HNRNPD predicts the prognosis of NSCLC patients. Following that, we knocked down HNRNPD in NSCLC cell lines in vitro and validated its biological function using CCK-8, transwell assays, wound healing tests, and Western blotting. Finally, we constructed tissue microarrays (TMAs) from 174 NSCLC patients and verified our findings using immunohistochemistry staining for HNRNPD from public databases. In both the public datasets, NSCLC tissues with elevated HNRNPD expression had shorter overall survival (OS). In addition, HNRNPD knockdown NSCLC cell lines showed significantly reduced proliferation, invasion, and metastatic capacity via the PI3K-AKT pathway. Finally, elevated HNRNPD expression in NSCLC TMAs was linked to a poorer prognosis and decreased PD-L1 expression levels. HNRNPD is associated with a poorer prognosis in NSCLC and affects tumor growth and metastasis via the PI3K-AKT pathway.
BACKGROUND: Cancer-associated fibroblasts (CAFs) are one of the major components of prostate stromal cells, which play a crucial part in tumor development and treatment resistance. This study aimed to establish a model of CAFs-related microRNAs (miRNAs) to assess prognostic differences, tumor microenvironments, and screening of anticancer drugs by integrating data from single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (buRNA-seq).
METHODS: scRNA-seq and buRNA-seq data of primary prostate cancer (PCa) were downloaded from Gene Expression Omnibus and The Cancer Genome Atlas databases. Statistical methods including Least absolute shrinkage and selection operator (Lasso), Lasso penalized, Random Forest, Random Forest Combination, and Support Vector Machine (SVM) were performed to select hub miRNAs. Pathway analyses and assessment of infiltrating immune cells were conducted using Gene Set Enrichment Analysis and the CIBERSORT algorithm. The expression of CAFs-related miRNAs in fibroblast cell lines were validated through quantitative real-time PCR. Cell Counting Kit 8 (CCK8), wound-healing, clone formation, and cell migration assays were used to explore cell proliferation, growth, and migration in vitro. A mouse xenograft model was established to investigate the effect of CAFs on tumor growth in vivo.
RESULTS: Through single-cell transcriptomics analysis in 34 PCa patients, 89 CAFs-related mRNAs were identified. A prognostic model based on 9 CAFs-related miRNAs (hsa-miR-1258, hsa-miR-133b, hsa-miR-222-3p, hsa-miR-145-3p, hsa-miR-493-5p, hsa-miR-96-5p, hsa-miR-15b-5p, hsa-miR-106b-5p, and hsa-miR-191-5p) was established to predict biochemical recurrence (BCR). We have determined through two prediction methods that NVP-TAE684 may be the optimal targeted therapy drug for treating CAFs. Downregulation of hsa-miR-106b-5p in CAFs significantly suppressed cell proliferation, migration, and colony formation in vitro. In vivo studies using a xenograft model further confirmed that hsa-miR-106b-5p downregulation significantly reduced tumor growth.
CONCLUSION: Our findings conducted an integrated bioinformatic analysis to develop a CAFs-related miRNAs model that provides prognostic insights into individualized and precise treatment for prostate adenocarcinoma patients. Downregulation of miR-106b-5p in CAFs significantly suppressed tumor growth, suggesting a potential therapeutic target for cancer treatment.
Human complement fragment 5a (C5a) is one of the most potent glycoproteins generated downstream of C3a and C4a during late-stage activation of the complement signaling cascade. C5a recruits receptors like C5aR1 and C5aR2 and is established to play a critical role in complement-mediated inflammation. Thus, excessive C5a in the plasma due to aberrant activation of the complement contributes to the pathophysiology of several chronic inflammatory diseases. Therefore, restricting the excessive interaction of C5a with its receptors by neutralizing C5a has been one of the most effective therapeutic strategies for the management of inflammatory diseases. Indeed, antibodies targeting C5 (Eculizumab), the precursor of C5a, and C5a (Vilobelimab) have already been approved by the FDA. Still, small designer peptides that work like antibodies and can target and stop C5a from interacting with its receptors seem to be a possible therapeutic alternative to antibodies because they are smaller, cheaper to make, more specific to their target, and can get through membrane barriers. As a proof-of-principle, the current study describes the computational design and evaluation of a pair of peptides that are able to form stable high-affinity complexes with the epitope regions of C5a that are important for the recruitment of C5aR1 and C5aR2. The computational data further supports the potential of designer peptides for mimicking the function of antibodies targeting C5a. However, further experimental studies will be required to establish the structure-function relationship of the designer peptides and also to establish the hypothesis of antibody-like peptides targeting C5a.
Phototherapy will be administered with a portable nine-diode cluster. The portable nine-diode cluster will be used overlapping three quadrants of the knee in random sequence: medial quadrant, lateral quadrant and posterior quadrant), with one 905-nm diode (mean power: 0 milliwatt; peak power: 0 watt; spot size: 0.44 cm2), four 875-nm diodes (mean power of each diode: 0 milliwatt; spot size: 1 cm2) and four 670-nm diodes (mean power of each diode: 0 milliwatt; spot size: 1 cm2); frequency: 0 Hz; 300-second irradiation time in each quadrant; total energy: 0 Joules per quadrant. Phototherapy will be included in the exercises group.
The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses. The subject in single agent dose levels will be administered multiple oral doses of LM-061 once daily.
This group will intake two sachets (2x4.4g) of a placebo each day for 12 weeks. The placebo is in the same powdered form as the food supplement taken by the intervention group. The two sachets will either be taken together or one in the morning and one in the evening.
PROBLEM TO BE SOLVED: To prepare a chemical peeling agent composition capable of acting a chemical peeling agent without causing inflammation due to deep infiltration of the peeling agent into the skin by including both a chemical peeling agent and an ascorbic acid derivative. SOLUTION: This chemical peeling agent composition is prepared by including (A) 0.1-80 wt.% chemical peeling agent and (B) 0.1-20 wt.% L-ascorbic acid derivative. 2-Hydroxycarboxylic acid compound (derivative) [e.g. 2- hydroxyethanoic acid (glycolic acid)] or the like is preferably used as the ingredient A. Sodium L-ascorbic acid-2-monophosphate, or the like, is preferably used as the ingredient B. The compound is applicable to such skin diseases as fine wrinkles of skin, freckle, liver spot, various pigmentation such as senile pigment macule, acne, dermatitis mark, scald, heat injury, trauma, their cicatrix.
Risk Summary

There are no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production. Semaglutide was present in the milk of lactating rats. SNAC and/or its metabolites concentrated in the milk of lactating rats. When a substance is present in animal milk, it is likely that the substance will be present in human milk (see Data). There are no data on the presence of SNAC in human milk. Since the activity of UGT2B7, an enzyme involved in SNAC clearance, is lower in infants compared to adults, higher SNAC plasma levels may occur in neonates and infants. Because of the unknown potential for serious adverse reactions in the breastfed infant due to the possible accumulation of SNAC from breastfeeding and because there are alternative formulations of semaglutide that can be used during lactation, advise patients that breastfeeding is not recommended during treatment with RYBELSUS.

Data

In lactating rats, semaglutide was detected in milk at levels 3 to 12-fold lower than in maternal plasma. SNAC and/or its metabolites were detected in milk of lactating rats following a single maternal administration on lactation day 10. Mean levels of SNAC and/or its metabolites in milk were approximately 2 to 12-fold higher than in maternal plasma.
The application describes ceDNA vectors having linear and continuous structure for delivery and expression of a transgene. ceDNA vectors comprise an expression cassette flanked by two ITR sequences, where the expression cassette encodes a transgene encoding PAH protein. Some ceDNA vectors further comprise cis-regulatory elements, including regulatory switches. Further provided herein are methods and cell lines for reliable gene expression of PAH protein in vitro, ex vivo and in vivo using the ceDNA vectors. Provided herein are method and compositions comprising ceDNA vectors useful for the expression of PAH protein in a cell, tissue or subject, and methods of treatment of diseases with said ceDNA vectors expressing PAH protein. Such PAH protein can be expressed for treating disease, e.g., Phenylketonuria (PKU).
PROBLEM TO BE SOLVED: To obtain the subject lubricant capable of improving product yield by using a specific polyglycerine/fatty acid eater as the base. SOLUTION: This lubricant contains behenic acid which accounting for at least 60% of the constituent fatty acids, and a lipophilic polyglycerine/fatty acid ester, as the main ingredient, having a hydroxy value of 100 or less and grain size of 250 μm or less. The polyglycerine constituting the polyglycerine/ fatty acid ester preferably has an average degree of polymerization of 2 to 10, estimated based on the hydroxy value. The polyglycerine/fatty acid ester is preferably incorporated in the powder or the like as the stock at 0.3 to 5 wt.%. The lubricant may be incorporated with a disintegrating agent, vehicle, absorbent or another lubricant, e.g. calcium carbonate.
Plasmodium parasites infect thousands of species and provide an exceptional system for studying host-pathogen dynamics, especially for multi-host pathogens. However, understanding these interactions requires an accurate assay of infection. Assessing Plasmodium infections using microscopy on blood smears often misses infections with low parasitemias (the fractions of cells infected), and biases in malaria prevalence estimates will differ among hosts that differ in mean parasitemias. We examined Plasmodium relictum infection and parasitemia using both microscopy of blood smears and quantitative polymerase chain reaction (qPCR) on 299 samples from multiple bird species in Hawai'i and fit models to predict parasitemias from qPCR cycle threshold (Ct) values. We used these models to quantify the extent to which microscopy underestimated infection prevalence and to more accurately estimate infection patterns for each species for a large historical study done by microscopy. We found that most qPCR-positive wild-caught birds in Hawaii had low parasitemias (Ct scores ≥35), which were rarely detected by microscopy. The fraction of infections missed by microscopy differed substantially among eight species due to differences in species' parasitemia levels. Infection prevalence was likely 4-5-fold higher than previous microscopy estimates for three introduced species, including Zosterops japonicus, Hawaii's most abundant forest bird, which had low average parasitemias. In contrast, prevalence was likely only 1.5-2.3-fold higher than previous estimates for Himatione sanguinea and Chlorodrepanis virens, two native species with high average parasitemias. Our results indicate that relative patterns of infection among species differ substantially from those observed in previous microscopy studies, and that differences depend on variation in parasitemias among species. Although microscopy of blood smears is useful for estimating the frequency of different Plasmodium stages and host attributes, more sensitive quantitative methods, including qPCR, are needed to accurately estimate and compare infection prevalence among host species.
Glaucoma is a major public health issue worldwide and manifests clinically as a chronic progressive optic neuropathy with concomitant visual field (VF) loss. Glaucoma can cause significant visual disability and decreased quality of life (1). Based on WHO's report in 2002, glaucoma is the second cause of blindness. The key to prevention of visual loss from glaucoma is early detection of the disease or its progression and timely treatment. Glaucoma can be quite advanced at the time of initial detection. The prevalence of advanced glaucoma at the time of diagnosis varies but can be quite high. For example, the average VF mean deviation (MD) in patients diagnosed with glaucoma in the Los Angeles Latino Eye Study was -9.6 dB (2), which represents moderately advanced to severe glaucoma. Detection of progression in advanced stages of glaucoma continues to be challenging. Visual field examination remains the gold standard for detection of progression in advanced glaucoma. However, long-term VF variability or noise in such eyes is significant, which could confound detection of change. The optic nerve head and peripapillary retinal nerve fiber layer (RNFL) demonstrate significant damage in such eyes and hence are not helpful for detection of change. About 50% of retinal ganglion cells (RGCs) are located within 4-5 mm of the macular center (3). Since the macular RGCs are the last ones to be affected in glaucoma, measurement of macular retinal thickness or retinal sublayers could provide significant information with regard to the course of advanced glaucoma.

The macular retinal sublayers can now be measured with reasonable accuracy with SD- OCTs. There is some evidence that measurement of the macular ganglion cell complex (GCC, combined thickness of RNFL, RGC and inner plexiform layer or IPL), or macular retinal thickness or volume may detect early glaucoma with a performance that approximates that of circumpapillary RNFL thickness measurements (4,5). In addition, such macular measurements have proved to be very reproducible (4,6). Given this excellent reproducibility, macular outcome measures would be the main candidates for following glaucoma eyes with advanced damage, in which the macular region is essentially the only retinal area with residual RGCs.